RC-0315 / Remedy Cell - LARVOL DELTA

Remedy Cell and Qureight collaborate to integrate deep learning platform into Phase 1b study of RC-0315 in IPF (PRNewswire) - "Remedy Cell...and Qureight Ltd...have partnered to validate RC-0315's mechanism of action in idiopathic pulmonary fibrosis (IPF). The primary objective of the RC-0315 Phase 1b clinical study is to measure drug safety and tolerability. The study's exploratory objectives will assess the effect of RC-0315 on disease pathology, measured through imaging and biomarker analysis in bronchoalveolar lavage (BAL) and plasma samples."

Commercial • Idiopathic Pulmonary Fibrosis